Nektar Therapeutics (NKTR)

41.69
NASDAQ : Health Technology
Prev Close 42.62
Day Low/High 40.04 / 43.30
52 Wk Low/High 29.22 / 111.36
Avg Volume 1.90M
Exchange NASDAQ
Shares Outstanding 173.09M
Market Cap 7.38B
EPS -0.60
P/E Ratio 10.32
Div & Yield N.A. (N.A)
EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ:NKTR) from November 11, 2017 through October 2, 2018, inclusive (the "Class Period").

Nektar To Announce Financial Results For The Third Quarter 2018 On Wednesday, November 7, 2018, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The Third Quarter 2018 On Wednesday, November 7, 2018, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018, after the close of U.

Nektar Therapeutics Becomes #47 Most Shorted S&P 500 Component, Replacing Expeditors International Of Washington

Nektar Therapeutics Becomes #47 Most Shorted S&P 500 Component, Replacing Expeditors International Of Washington

The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Behind the Selloff: Cramer's 'Mad Money' Recap (Thursday 10/4/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Thursday 10/4/18)

Jim Cramer lists the things we need to see before the bear backs off and the market regains its footing.

Anheuser-Busch InBev, Alteryx, Walker & Dunlop: 'Mad Money' Lightning Round

Anheuser-Busch InBev, Alteryx, Walker & Dunlop: 'Mad Money' Lightning Round

Jim Cramer weighs in on Anheuser-Busch InBev, Alteryx, Walker & Dunlop, Kratos Defense & Security, Johnson Controls, Nektar Therapeutics, Align Technology.

The New #48 Most Shorted S&P 500 Component: Nektar Therapeutics

The New #48 Most Shorted S&P 500 Component: Nektar Therapeutics

The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

INVESTOR ALERT: Investigation Of Nektar Therapeutics Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Nektar Therapeutics Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) complied with the federal securities laws.

Nektar Therapeutics (NKTR) Investigated By Block & Leviton LLP For Violations Of Federal Securities Laws

Nektar Therapeutics (NKTR) Investigated By Block & Leviton LLP For Violations Of Federal Securities Laws

BOSTON, Oct. 3, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Nektar Therapeutics - NKTR

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Nektar Therapeutics - NKTR

NEW YORK, Oct. 3, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("NKTR" or the "Company") (NASDAQ: NKTR).

Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI

Stitch Fix Tumbles; Nektar Finally Adds a Woman to Board -- ICYMI

Here's what you need to know now for Tuesday, Oct. 2.

Nektar Therapeutics Announces Ten Abstracts Accepted For Presentation At The 2018 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

Nektar Therapeutics Announces Ten Abstracts Accepted For Presentation At The 2018 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

SAN FRANCISCO, Oct. 2, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer...

Nektar Therapeutics Strengthens Board Of Directors With Appointment Of Veteran Biotechnology Executive Karin Eastham

Nektar Therapeutics Strengthens Board Of Directors With Appointment Of Veteran Biotechnology Executive Karin Eastham

SAN FRANCISCO, Oct. 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has appointed Karin Eastham as an independent director to its Board of Directors.

U.S.-Canada Trade Deal, Tesla, Women on Company Boards - 5 Things You Must Know

U.S.-Canada Trade Deal, Tesla, Women on Company Boards - 5 Things You Must Know

U.S. stock futures rise sharply after the U.S. reaches an agreement with Canada to revamp the North American Free Trade Agreement; Tesla soars after CEO Elon Musk settles with the SEC; California bill requires women on company boards.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXL, BIG, DK, FOSL, NFG, NKTR, SRC, TGH, UTSI Downgrades: AIRG, AXAS, HPP, PAA, QDEL, RAD Initiations: FND, RETA, TOCA Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics Takes Over #53 Spot From Leggett & Platt

Nektar Therapeutics Takes Over #53 Spot From Leggett & Platt

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #53 spot from Leggett & Platt, Inc. , according to ETF Channel.

Nektar Is the One S&P 500 Company Without a Woman Director

Nektar Is the One S&P 500 Company Without a Woman Director

Nektar Therapeutics remains the only S&P 500 company without a woman on the board, according to BoardEx, a relationship mapping service of TheStreet.

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Tech Alone Can't Save the Rally: Cramer's 'Mad Money' Recap (Tuesday 6/5/18)

Jim Cramer says the tech titans are leading the way, but out side of the tech sector, very few stocks are following.

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Hasbro, Dropbox, Carlyle Group: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hasbro, Dropbox, Carlyle Group, Corning, Banco Santander, Goldman Sachs, Edwards Lifesciences, J. Jill and more.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug

Nektar Therapeutics shares got destroyed on Monday. Here is why.

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.

Nektar Therapeutics Moves Up In Analyst Rankings, Passing Thermo Fisher Scientific

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #12 spot from Thermo Fisher Scientific Inc , according to ETF Channel. Below is a chart of Nektar Therapeutics versus Thermo Fisher Scientific Inc plotting their respective rank within the S&P 500 over time (NKTR plotted in blue; TMO plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

GE and Kohl's Are Among 2 Stocks Poised For Reversal

GE and Kohl's Are Among 2 Stocks Poised For Reversal

These names are showing bullish and bearish technical patterns over the past week.

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains

Stocks finished higher on Wednesday.

Nektar Shares Surge on Bristol-Myers Collaboration

Nektar Shares Surge on Bristol-Myers Collaboration

Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb And Nektar Therapeutics Announce Global Development & Commercialization Collaboration For Nektar's CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

Rev's Forum: Problems Simmer, but It's Still Too Early for a Bearish Bias

It is premature to think that this market has hit a top until there is further evidence in the price action.

TheStreet Quant Rating: D+ (Sell)